Anzeige
Mehr »
Dienstag, 03.02.2026 - Börsentäglich über 12.000 News
KI für Verteidigung: Der Countdown zu einer der heißesten AI-Hightech-Stories 2026 beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
59 Leser
Artikel bewerten:
(0)

CellaVision AB: CellaVision introduces CellaVision Image Capture System for smaller laboratories within a hospital network

Product demonstrations will be taking place at the following shows:
ISLH, Nice, France, May 21-24, AACC, Los Angeles, USA, July 15-19 and IFBLS Congress, Berlin, Germany, Aug. 18-22.

CellaVision, which develops and sells products for routine analysis of blood and other body fluids in health care, is introducing the CellaVision® Image Capture System, its new cell morphology system for networked hospitals and associated laboratories. The product gives laboratories within the same network, no matter of size, the ability to share, review and store their manual blood tests, known as differential counts.

The new product is designed for smaller laboratories performing up to 15 cell differentials per day complementing the company's current digital cell morphology products that are marketed to laboratories with large and medium-size workloads.

"With the CellaVision® Image Capture System, CellaVision may now propose solutions to a greater variety of customer needs, including those of the smaller labs", says Peter Wilson, Marketing Manager at CellaVision. "Promoting collaboration and resource sharing, the system will allow the smaller laboratories to digitize their samples and have the analysis performed at the main lab. This means even the smallest labs can now become best practice in cell morphology."

The CellaVision Image Capture System is designed to utilize a laboratory's existing microscope. CellaVision software helps the technologist to find, focus and capture cell images, and then transmits the digital cells to a CellaVision DM96 or DM1200 in a main lab at another location where the review is performed.

New Product Overview
Name: CellaVision® Image Capture System
Target market: All regions. Networked hospital groups and health authorities consisting of both large and small laboratories.
Launch: Beginning July 2012 (specific market availability will vary)

Laboratory Benefits:

  • Reduce turnaround time and patient wait
  • Ensure quality throughout a health network
  • Reduce the need for morphology expertise in the smaller lab

Please find additional information at the product campaign site www.cellavision.com/newproduct (http://www.cellavision.com/newproduct). A printable photo can be downloaded via the link below.


For more information, please contact:
Peter Wilson, Marketing Manager, CellaVision AB
Phone: +46 709 92 24 54. E-mail: peter.wilson@cellavision.com (mailto:peter.wilson@cellavision.com)


About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells best-in-class systems for the routine analysis of blood and other body fluids. These analyses are often critical results used in the correct and timely diagnosis of illnesses such as infections and cancer. CellaVision's products reduce manual laboratory work, standardize results and support an efficient laboratory workflow. The company has leading-edge expertise in digital image analysis, artificial intelligence and automated microscopy. In 2011, net sales were 155 MSEK and sales continue to grow with the target to increase by at least 15 % per year over an economic cycle. CellaVision has its head office in Lund, Sweden, and subsidiaries in the US, Canada and Japan. The company share is listed on Nasdaq OMX Stockholm, Small Cap. For more information, please visit www.cellavision.com (http://www.cellavision.com/).  

Photo CellaVision Image Capture System (http://hugin.info/132164/R/1612817/513794.jpg)



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: CellaVision AB via Thomson Reuters ONE

HUG#1612817
© 2012 GlobeNewswire (Europe)
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.